Modified port implantation for intraperitoneal chemotherapy: a retrospective analysis of cycle completion and survival in ovarian cancer

Background: Intraperitoneal chemotherapy (IPCT) has been shown to improve survival in patients with stage III and IV ovarian cancers. However, its utilization has declined due to high discontinuation rates often attributed to catheter related complications, toxicity of IPCT, and decreased quality of life from abdominal pain. A modified port insertion technique may help reduce chemotherapy and port complications, offering chemotherapy in outpatient settings. Methods: This retrospective study included 72 patients who underwent IPCT at a single institution, Women’s Cancer Centre from January 2005 to May 2016. Results: The median number of IPCT cycles administered was six. Completion rates were as follows: 52 patients (73.2%) completed 4 cycles, 47 patients (66.2%) completed 6 cycles, and 29 patients (40.84%) completed 8 cycles. Patients receiving 7 cycles or more had a significantly longer average survival period (64.76 ± 5.38 months) compared to those receiving 6 cycles or fewer (41.27 ± 5.77 months) (p = 0.004). Port-related issues were the primary reason for therapy discontinuation in the majority of cases (11.1%) in concord with other studies. Additional factors associated with discontinuation before 7 cycles included neoadjuvant chemotherapy, presence of adhesions, port and systemic infections, severe abdominal pain, and family history of genitourinary cancer. Conclusions: The modified port implantation technique increases delivery of IPCT cycles, potentially enhancing treatment efficacy. IPCT provides a promising, office-based maintenance therapy option with significant survival benefits.

Ovarian neoplasms; Maintenance chemotherapy; Intraperitoneal catheterization; Survival

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015; 65: 5–29.

[2] Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology. 2003; 21: 3194–3200.

[3] Breusa S, Zilio S, Catania G, Bakrin N, Kryza D, Lollo G. Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer. Frontiers in Oncology. 2023; 13: 1125868.

[4] Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, et al. Transforming ovarian cancer care by targeting minimal residual disease. Med. 2023; 4: 755–760.

[5] Dedrick RL, Myers CE, Bungay PM, Devita VT III. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treatment Reports. 1978; 62: 1–11.

[6] Kumar KP, Madhusoodanan M, Pangath M, Menon D. Innovative landscapes in intraperitoneal therapy of ovarian cancer. Drug Delivery and Translational Research. 2025; 6: 1877–1906.

[7] De Jong LaW, Lambert M, Van Erp NP, De Vries L, Chatelut E, Ottevanger PB. Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer Chemotherapy and Pharmacology. 2023; 91: 247–256.

[8] Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin—a Sankai Gynecology Study Group (SGSG) study. Gynecologic Oncology. 2005; 99: 591–596.

[9] Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. Journal of Clinical Oncology. 2015; 33: 2841–2847.

[10] Alberts DS, Liu PY, Hannigan EV, O’toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. The New England Journal of Medicine. 1996; 335: 1950–1955.

[11] Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. The New England Journal of Medicine. 2006; 354: 34–43.

[12] Markman M ,Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. Journal of Clinical Oncology. 2006; 24: 988–994.

[13] Pitiyarachchi O, Friedlander M, Java JJ, Chan JK, Armstrong DK, Markman M, et al. What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. Gynecologic Oncology. 2022; 166: 410–416.

[14] Marchetti C, De Felice F, Perniola G, Palaia I, Musella A, Di Donato V, et al. Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: a meta-analysis. Critical Reviews in Oncology/Hematology. 2019; 136: 64–69.

[15] Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a gynecologic oncology group study. Gynecologic Oncology. 2006; 100: 27–32.

[16] National Cancer Institute. Clinical announcement on intraperitoneal chemotherapy in ovarian cancer. 2006. Available at: https://ctep.cancer.gov/highlights/docs/clin_annc_010506.pdf (Accessed: 15 May 2025).

[17] Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open. 2022; 7: 100586.

[18] Solass W, Kerb R, Murdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Annals of Surgical Oncology. 2014; 21: 553–559.

[19] Fujiwara K, Nagao S, Tan D, Hasegawa K. Intraperitoneal chemotherapy is now back for ovarian cancer. International Journal of Clinical Oncology. 2025; 30: 427–433.

[20] Di Giorgio A, Macri A, Ferracci F, Robella M, Visaloco M, De Manzoni G, et al. 10 years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): a systematic review and meta-analysis. Cancers. 2023; 15: 1125.

[21] Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA, et al. Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers. 2021; 13: 4318.

[22] Milczek T, Klasa-Mazurkiewicz D, Emerich J, Kobierski J. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica. 2009; 88: 463–467.

[23] Sakuragi N, Nakajima A, Nomura E, Noro N, Yamada H, Yamamoto R, et al. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma. Gynecologic Oncology. 2000; 79: 420–423.

[24] Yen MS, Twu NF, Lai CR, Horng HC, Chao KC, Juang CM. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. Gynecologic Oncology. 2009; 114: 415–419.

[25] Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. Journal of Clinical Oncology. 2015; 33: 1460–1466.

[26] Makhija S, Sabbatini P, Aghajanian C, Venkatraman E, Spriggs DR, Barakat R. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look. Gynecologic Oncology. 2000; 79: 28–32.

[27] Landrum LM, Gold MA, Moore KN, Myers TK, Mcmeekin DS, Walker JL. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecologic Oncology. 2008; 108: 342–347.

[28] Ivy JJ, Geller M, Pierson SM, Jonson AL, Argenta PA. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution’s experience. Gynecologic Oncology. 2009; 114: 420–423.

[29] Skaznik-Wikiel ME, Lesnock JL, Mcbee WC, Beriwal S, Zorn KK, Richard SD, et al. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes. International Journal of Gynecological Cancer. 2012; 22: 232–237.

[30] Lee J, Curtin JP, Muggia FM, Pothuri B, Boyd LR, Blank SV. Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer. Cancer Chemotherapy and Pharmacology. 2018; 82: 55–63.

[31] Nagao S, Fujiwara K, Yamamoto K, Tanabe H, Okamoto A, Takehara K, et al. Intraperitoneal carboplatin for ovarian cancer—a phase 2/3 trial. NEJM Evidence. 2023; 2: EVIDoa2200225.

[32] Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, Disilvestro PA, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology/gynecologic oncology group study. Journal of Clinical Oncology. 2019; 37: 1380–1390.

[33] Mueller JJ, Kelly A, Zhou Q, Iasonos A, Long Roche K, Sonoda Y, et al. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: feasibility and outcomes at a comprehensive cancer center. Gynecologic Oncology. 2016; 143: 496–503.

[34] Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. Journal of Clinical Oncology. 2010; 28: 3555–3561.

[35] Lindstrom LS, Hall P, Hartman M, Wiklund F, Gronberg H, Czene K. Familial concordance in cancer survival: a Swedish population-based study. The Lancet Oncology. 2007; 8: 1001–1006.

[36] Graham CD, Ellison R, Hall LH, Clark J, Mcnaught E, Green SMC, et al. A pilot randomised controlled trial of acceptance and commitment therapy for medication decision-making and quality of life in women with breast cancer: the ACTION trial. Psychooncology. 2024; 33: e6349.

[37] Williamson SK, Johnson GA, Maulhardt HA, Moore KM, Mcmeekin DS, Schulz TK, et al. A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies. Cancer Chemotherapy and Pharmacology. 2015; 75: 1075–1087.

[38] Galvagno F, Leuci V, Massa A, Donini C, Rotolo R, Capellero S, et al. Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis. Cancer Immunology, Immunotherapy. 2024; 74: 6.

[39] Sorrin AJ, Zhou K, May K, Liu C, Mcnaughton K, Rahman I, et al. Transient fluid flow improves photoimmunoconjugate delivery and photoimmunotherapy efficacy. iScience. 2023; 26: 107221.

[40] Wang L, Ma S, Su H, Nie D, Wang L. The impact of bevacizumab intraperitoneal perfusion combined with paclitaxel and platinum-based chemotherapy on serum stromal-derived factor-1a (SDF-1a) and chemokine ligand 5 (CXCL-5) levels in patients with ovarian cancer after tumor cell debulking surgery. Anticancer Drugs. 2025; 36: 232–237.